Derks and colleagues observed that patients with LCNEC tumors that carry a wild-type RB1 gene or express the Rb protein have a more favorable outcome when treated with platinum plus gemcitabine or taxanes compared to standard platinum plus etoposide chemotherapy, whereas no differences were observed when RB1 was mutated or the Rb protein not expressed [33]. Here, RB1 is linked to large cell neuroendocrine carcinoma.